Publication Cover
Expert Review of Precision Medicine and Drug Development
Personalized medicine in drug development and clinical practice
Volume 3, 2018 - Issue 3
142
Views
4
CrossRef citations to date
0
Altmetric
Review

Population-level pharmacogenomics for precision drug development in dementia

Pages 163-188 | Received 24 Jan 2018, Accepted 19 Apr 2018, Published online: 08 May 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Ramón Cacabelos. (2022) What have we learnt from past failures in Alzheimer’s disease drug discovery?. Expert Opinion on Drug Discovery 17:4, pages 309-323.
Read now
Ramón Cacabelos, Iván Carrera, Olaia Martínez-Iglesias, Natalia Cacabelos & Vinogran Naidoo. (2021) What is the gold standard model for Alzheimer’s disease drug discovery and development?. Expert Opinion on Drug Discovery 16:12, pages 1415-1440.
Read now
Ramón Cacabelos. (2020) Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:8, pages 673-701.
Read now
Ramon Cacabelos. (2020) Pharmacogenomics of drugs used to treat brain disorders. Expert Review of Precision Medicine and Drug Development 5:3, pages 181-234.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.